Rotavirus Infection. An Update on Management and Prevention

Advances in Pediatrics

Volumn 59, Issue 1, 2012, Pages 47-74

  Dennehy, Penelope H ^a,b  

^a HASBRO CHILDREN'S HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Rotavirus; Rotavirus gastroenteritis; Rotavirus vaccine

Indexed keywords

ROTAVIRUS VACCINE;

CLASSIFICATION; DIARRHEA; DRUG CONTRAINDICATION; DRUG EFFECT; HERD IMMUNITY; HUMAN; IMMUNOLOGY; INFANT; PRESCHOOL CHILD; REVIEW; ROTAVIRUS; ROTAVIRUS INFECTION; UNITED STATES; VIROLOGY;

CHILD, PRESCHOOL; DIARRHEA; HUMANS; IMMUNITY, HERD; INFANT; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; UNITED STATES;

EID: 84863843205     PISSN: 00653101     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yapd.2012.04.002     Document Type: Review

References (135)

1. Parashar U.D., Gibson C.J., Bresse J.S., et al. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006, 12(2):304-306.
2. Glass R.I., Bresee J., Jiang B., et al. Rotavirus and rotavirus vaccines. Adv Exp Med Biol 2006, 582:45-54.
3. Centers for Disease Control and Prevention Rotavirus surveillance - worldwide, 2009. MMWR Morb Mortal Wkly Rep 2011, 60(16):514-516.
4. Fischer T.K., Viboud C., Parashar U., et al. Hospitalizations and deaths from diarrhea and rotavirus among children <5 Years of Age in the United States, 1993-2003. J Infect Dis 2007, 195(8):1117-1125.
5. Malek M.A., Curns A.T., Holman R.C., et al. Diarrhea- and rotavirus-associated hospitalizations among children less than 5 years of age: United States, 1997 and 2000. Pediatrics 2006, 117(6):1887-1892.
6. Glass R.I., Kilgore P.E., Holman R.C., et al. The epidemiology of rotavirus diarrhea in the United States: surveillance and estimates of disease burden. J Infect Dis 1996, 174(Suppl 1):S5-S11.
7. Cortese M.M., Parashar U.D. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2009, 58(RR-2):1-25.
8. Payne D.C., Staat M.A., Edwards K.M., et al. Active, population-based surveillance for severe rotavirus gastroenteritis in children in the United States. Pediatrics 2008, 122(6):1235-1243.
9. Mast T.C., Walter E.B., Bulotsky M., et al. Burden of childhood rotavirus disease on health systems in the United States. Pediatr Infect Dis J 2010, 29(2):e19-e25.
10. Coffin S.E., Elser J., Marchant C., et al. Impact of acute rotavirus gastroenteritis on pediatric outpatient practices in the United States. Pediatr Infect Dis J 2006, 25(7):584-589.
11. Widdowson M.A., Meltzer M.I., Zhang X., et al. Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics 2007, 119(4):684-697.
12. Turcios R.M., Curns A.T., Holman R.C., et al. Temporal and geographic trends of rotavirus activity in the United States, 1997-2004. Pediatr Infect Dis J 2006, 25(5):451-454.
13. American Academy of Pediatrics Rotavirus infections. Red Book: 2009 Report of the Committee on Infectious Diseases 2009, 576-579. American Academy of Pediatrics, Elk Grove Village (IL). 28th edition. L. Pickering (Ed.).
14. Dennehy P.H., Nelson S.M., Crowley B.A., et al. Detection of rotavirus RNA in hospital air samples by polymerase chain reaction (PCR). Pediatr Res 1998, 43:143A.
15. Ford-Jones E.L., Wang E., Petric M., et al. Rotavirus-associated diarrhea in outpatient settings and child care centers. The Greater Toronto Area/Peel Region PRESI Study Group. Pediatric Rotavirus Epidemiology Study for Immunization. Arch Pediatr Adolesc Med 2000, 154(6):586-593.
16. Fischer T.K., Bresee J.S., Glass R.I. Rotavirus vaccines and the prevention of hospital-acquired diarrhea in children. Vaccine 2004, 22(Suppl 1):S49-S54.
17. Zerr D.M., Allpress A.L., Heath J., et al. Decreasing hospital-associated rotavirus infection: a multidisciplinary hand hygiene campaign in a children's hospital. Pediatr Infect Dis J 2005, 24(5):397-403.
18. Fischer T.K., Steinsland H., Valentiner-Branth P. Rotavirus particles can survive storage in ambient tropical temperatures for more than 2 months. J Clin Microbiol 2002, 40(12):4763-4764.
19. Ramig R.F. Pathogenesis of intestinal and systemic rotavirus infection. J Virol 2004, 78(19):10213-10220.
20. Bishop R.F., Davidson G.P., Holmes I.H., et al. Letter: evidence for viral gastroenteritis. N Engl J Med 1973, 289(20):1096-1097.
21. Ball J.M., Tian P., Zeng C.Q., et al. Age-dependent diarrhea induced by a rotaviral nonstructural glycoprotein. Science 1996, 272(5258):101-104.
22. Lundgren O., Peregrin A.T., Persson K., et al. Role of the enteric nervous system in the fluid and electrolyte secretion of rotavirus diarrhea. Science 2000, 287(5452):491-495.
23. Blutt S.E., Kirkwood C.D., Parreno V., et al. Rotavirus antigenaemia and viraemia: a common event?. Lancet 2003, 362(9394):1445-1449.
24. Blutt S.E., Matson D.O., Crawford S.E., et al. Rotavirus antigenemia in children is associated with viremia. PLoS Med 2007, 4(4):e121.
25. Chiappini E., Azzari C., Moriondo M., et al. Viraemia is a common finding in immunocompetent children with rotavirus infection. J Med Virol 2005, 76(2):265-267.
26. Chiappini E., Galli L., de Martino M. Viremia and clinical manifestations in children with rotavirus infection. J Infect Dis 2006, 193(9):1333.
27. Moon S., Wang Y., Dennehy P., et al. Antigenemia, RNAemia, and innate immunity in children with acute rotavirus diarrhea. FEMS Immunol Med Microbiol 2012, 64(3):382-391.
28. Widdowson M.A., Bresee J.S., Gentsch J.R., et al. Rotavirus disease and its prevention. Curr Opin Gastroenterol 2005, 21(1):26-31.
29. Arakawa C., Fujita Y., Imai Y., et al. Detection of group a rotavirus RNA and antigens in serum and cerebrospinal fluid from two children with clinically mild encephalopathy with a reversible splenial lesion. Jpn J Infect Dis 2011, 64(3):204-207.
30. Ashida A., Fujieda M., Ohta K., et al. Clinical characteristics of obstructive uropathy associated with rotavirus gastroenteritis in Japan. Clin Nephrol 2012, 77(1):49-54.
31. Iturriza-Gomara M., Auchterlonie I.A., Zaw W., et al. Rotavirus gastroenteritis and central nervous system (CNS) infection: characterization of the VP7 and VP4 genes of rotavirus strains isolated from paired fecal and cerebrospinal fluid samples from a child with CNS disease. J Clin Microbiol 2002, 40(12):4797-4799.
32. Kato Z., Sasai H., Funato M., et al. Acute cerebellitis associated with rotavirus infection. World J Pediatr 2011, [Epub ahead of print].
33. Lynch M., Lee B., Azimi P., et al. Rotavirus and central nervous system symptoms: cause or contaminant? Case reports and review. Clin Infect Dis 2001, 33(7):932-938.
34. Lynch M., Shieh W.J., Tatti K., et al. The pathology of rotavirus-associated deaths, using new molecular diagnostics. Clin Infect Dis 2003, 37(10):1327-1333.
35. Medici M.C., Abelli L.A., Guerra P., et al. Case report: detection of rotavirus RNA in the cerebrospinal fluid of a child with rotavirus gastroenteritis and meningism. J Med Virol 2011, 83(9):1637-1640.
36. Pang X.L., Joensuu J., Vesikari T. Detection of rotavirus RNA in cerebrospinal fluid in a case of rotavirus gastroenteritis with febrile seizures. Pediatr Infect Dis J 1996, 15(6):543-545.
37. Ramig R.F. Systemic rotavirus infection. Expert Rev Anti Infect Ther 2007, 5(4):591-612.
38. Staat M.A., Azimi P.H., Berke T., et al. Clinical presentations of rotavirus infection among hospitalized children. Pediatr Infect Dis J 2002, 21(3):221-227.
39. Newman R.D., Grupp-Phelan J., Shay D.K., et al. Perinatal risk factors for infant hospitalization with viral gastroenteritis. Pediatrics 1999, 103(1):E3.
40. Bhan M.K., Lew J.F., Sazawal S., et al. Protection conferred by neonatal rotavirus infection against subsequent rotavirus diarrhea. J Infect Dis 1993, 168(2):282-287.
41. Bishop R.F., Barnes G.L., Cipriani E., et al. Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. N Engl J Med 1983, 309(2):72-76.
42. Anderson E.J., Weber S.G. Rotavirus infection in adults. Lancet Infect Dis 2004, 4(2):91-99.
43. Hrdy D. Epidemiology of rotaviral infection in adults. Rev Infect Dis 1987, 9:461-469.
44. King C.K., Glass R., Bresee J.S., et al. Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy. MMWR Recomm Rep 2003, 52(RR-16):1-16.
45. Guarino A., Lo Vecchio A., Canani R.B. Probiotics as prevention and treatment for diarrhea. Curr Opin Gastroenterol 2009, 25(1):18-23.
46. Szajewska H., Dziechciarz P. Gastrointestinal infections in the pediatric population. Curr Opin Gastroenterol 2010, 26(1):36-44.
47. Guandalini S. Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol 2011, 45(Suppl):S149-S153.
48. Rossignol J.F., Abu-Zekry M., Hussein A., et al. Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial. Lancet 2006, 368(9530):124-129.
49. Rossignol J.F., El-Gohary Y.M. Nitazoxanide in the treatment of viral gastroenteritis: a randomized double-blind placebo-controlled clinical trial. Aliment Pharmacol Ther 2006, 24(10):1423-1430.
50. Teran C.G., Teran-Escalera C.N., Villarroel P. Nitazoxanide vs. probiotics for the treatment of acute rotavirus diarrhea in children: a randomized, single-blind, controlled trial in Bolivian children. Int J Infect Dis 2009, 13(4):518-523.
51. Khanna R., Lakhanpaul M., Burman-Roy S., et al. Diarrhoea and vomiting caused by gastroenteritis in children under 5 years: summary of NICE guidance. BMJ 2009, 338:b1350.
52. Fedorowicz Z., Alhashimi D., Alhashimi H. Meta-analysis: ondansetron for vomiting in acute gastroenteritis in children. Aliment Pharmacol Ther 2007, 26(7):1086. [author reply: 1087].
53. Szajewska H., Gieruszczak-Bialek D., Dylag M. Meta-analysis: ondansetron for vomiting in acute gastroenteritis in children. Aliment Pharmacol Ther 2007, 25(4):393-400.
54. Hoshino Y., Kapikian A.Z. Rotavirus serotypes: classification and importance in epidemiology, immunity, and vaccine development. J Health Popul Nutr 2000, 18(1):5-14.
55. Gentsch J.R., Laird A.R., Bielfelt B., et al. Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccine programs. J Infect Dis 2005, 192(Suppl 1):S146-S159.
56. Gentsch J.R., Woods P.A., Ramachandran M., et al. Review of G and P typing results from a global collection of rotavirus strains: implications for vaccine development. J Infect Dis 1996, 174(Suppl 1):S30-S36.
57. Santos N., Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 2005, 15(1):29-56.
58. Linhares A.C., Verstraeten T., Wolleswinkel-van den Bosch J., et al. Rotavirus serotype G9 is associated with more-severe disease in Latin America. Clin Infect Dis 2006, 43(3):312-314.
59. Steele A.D., Ivanoff B. Rotavirus strains circulating in Africa during 1996-1999: emergence of G9 strains and P[6] strains. Vaccine 2003, 21(5-6):361-367.
60. Velazquez F.R., Matson D.O., Calva J.J., et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996, 335(14):1022-1028.
61. Ward R.L. Possible mechanisms of protection elicited by candidate rotavirus vaccines as determined with the adult mouse model. Viral Immunol 2003, 16(1):17-24.
62. Franco M.A., Angel J., Greenberg H.B. Immunity and correlates of protection for rotavirus vaccines. Vaccine 2006, 24(15):2718-2731.
63. Kapikian A.Z., Hoshino Y., Chanock R.M., et al. Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children. J Infect Dis 1996, 174(Suppl 1):S65-S72.
64. Joensuu J., Koskenniemi E., Pang X.L., et al. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 1997, 350(9086):1205-1209.
65. Perez-Schael I., Guntinas M.J., Perez M., et al. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med 1997, 337(17):1181-1187.
66. Rennels M.B., Glass R.I., Dennehy P.H., et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines-report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group. Pediatrics 1996, 97(1):7-13.
67. Santosham M., Moulton L.H., Reid R., et al. Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations. J Pediatr 1997, 131(4):632-638.
68. Centers for Disease Control and Prevention Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1999, 48(RR-2):1-20.
69. Centers for Disease Control and Prevention Intussusception among recipients of rotavirus vaccine-United States, 1998-1999. MMWR Morb Mortal Wkly Rep 1999, 48(27):577-581.
70. Murphy T.V., Gargiullo P.M., Wharton M. More on rotavirus vaccination and intussusception. N Engl J Med 2002, 346(3):211-212.
71. Kramarz P., France E.K., Destefano F., et al. Population-based study of rotavirus vaccination and intussusception. Pediatr Infect Dis J 2001, 20(4):410-416.
72. Murphy T.V., Gargiullo P.M., Massoudi M.S., et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001, 344(8):564-572.
73. Peter G., Myers M.G. Intussusception, rotavirus, and oral vaccines: summary of a workshop. Pediatrics 2002, 110(6):e67.
74. Vesikari T., Matson D.O., Dennehy P., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354(1):23-33.
75. Block S.L., Vesikari T., Goveia M.G., et al. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics 2007, 119(1):11-18.
76. Dennehy P.H., Vesikari T., Matson D.O., et al. Efficacy of the pentavalent rotavirus vaccine, RotaTeq(R) (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen). Hum Vaccin 2011, 7(5):563-568.
77. Armah G.E., Sow S.O., Breiman R.F., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376(9741):606-614.
78. Zaman K., Dang D.A., Victor J.C., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376(9741):615-623.
79. Bernstein D.I., Sack D.A., Rothstein E., et al. Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial. Lancet 1999, 354(9175):287-290.
80. Ruiz-Palacios G.M., Perez-Schael I., Velazquez F.R., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354(1):11-22.
81. Vesikari T., Karvonen A., Prymula R., et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007, 370(9601):1757-1763.
82. Phua K.B., Lim F.S., Lau Y.L., et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study. Vaccine 2009, 27(43):5936-5941.
83. Madhi S.A., Cunliffe N.A., Steele D., et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010, 362(4):289-298.
84. World Health Organization Rotavirus vaccines: an update. Wkly Epidemiol Rec 2009, 84(50):533-540.
85. Committee on Infectious Diseases of the American Academy of Pediatrics Prevention of rotavirus disease: updated guidelines for use of rotavirus vaccine. Pediatrics 2009, 123(5):1412-1420.
86. Saulsbury F.T., Winkelstein J.A., Yolken R.H. Chronic rotavirus infection in immunodeficiency. J Pediatr 1980, 97(1):61-65.
87. Patel N.C., Hertel P.M., Estes M.K., et al. Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. N Engl J Med 2010, 362(4):314-319.
88. Uygungil B., Bleesing J.J., Risma K.A., et al. Persistent rotavirus vaccine shedding in a new case of severe combined immunodeficiency: a reason to screen. J Allergy Clin Immunol 2010, 125(1):270-271.
89. Werther R.L., Crawford N.W., Boniface K., et al. Rotavirus vaccine induced diarrhea in a child with severe combined immune deficiency. J Allergy Clin Immunol 2009, 124(3):600.
90. Centers for Disease Control and Prevention Addition of severe combined immunodeficiency as a contraindication for administration of rotavirus vaccine. MMWR Morb Mortal Wkly Rep 2010, 59(22):687-688.
91. Centers for Disease Control and Prevention Addition of history of intussusception as a contraindication for rotavirus vaccination. MMWR Morb Mortal Wkly Rep 2011, 60(41):1427.
92. American Academy of Pediatrics Immunocompromised children. Red book: 2009 report of the Committee on Infectious Diseases 2009, 24-25. American Academy of Pediatrics, Elk Grove Village (IL). 28th edition. L.K. Pickering, C.J. Baker, D.W. Kimberlin (Eds.).
93. Steele A.D., Cunliffe N., Tumbo J., et al. A review of rotavirus infection in and vaccination of human immunodeficiency virus-infected children. J Infect Dis 2009, 200(Suppl 1):S57-S62.
94. Steele A.D., Madhi S.A., Louw C.E., et al. Safety, Reactogenicity, and Immunogenicity of Human Rotavirus Vaccine RIX4414 in Human Immunodeficiency Virus-positive Infants in South Africa. Pediatr Infect Dis J 2011, 30(2):125-130.
95. Goveia M.G., Rodriguez Z.M., Dallas M.J., et al. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatr Infect Dis J 2007, 26(12):1099-1104.
96. Omenaca F., Sarlangue J., Szenborn L., et al. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in pre-term European infants: a randomized phase IIIb study. Pediatr Infect Dis J 2012, 31(5):487-493.
97. Payne D.C., Edwards K.M., Bowen M.D., et al. Sibling transmission of vaccine-derived rotavirus (RotaTeq) associated with rotavirus gastroenteritis. Pediatrics 2010, 125(2):e438-e441.
98. Rivera L., Pena L.M., Stainier I., et al. Horizontal transmission of a human rotavirus vaccine strain-a randomized, placebo-controlled study in twins. Vaccine 2011, 29(51):9508-9513.
99. Centers for Disease Control and Prevention National and state vaccination coverage among children aged 19-35 months-United States, 2010. MMWR Morb Mortal Wkly Rep 2011, 60(34):1157-1163.
100. Buttery J.P., Danchin M.H., Lee K.J., et al. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. Vaccine 2011, 29(16):3061-3066.
101. Patel M.M., Lopez-Collada V.R., Bulhoes M.M., et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med 2011, 364(24):2283-2292.
102. Shui I.M., Baggs J., Patel M., et al. Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants. JAMA 2012, 307(6):598-604.
103. Loughlin J., Mast T.C., Doherty M., et al. Post marketing evaluation of the short-term safety of the pentavalent rotavirus vaccine. Pediatr Infect Dis J 2012, 31(3):292-296.
104. Victoria J.G., Wang C., Jones M.S., et al. Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. J Virol 2010, 84(12):6033-6040.
105. Kuehn B.M. FDA: benefits of rotavirus vaccination outweigh potential contamination risk. JAMA 2010, 304(1):30-31.
106. Patel M.M., Parashar U.D. Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs. J Infect Dis 2009, 200(Suppl 1):S291-S299.
107. Boom J.A., Tate J.E., Sahni L.C., et al. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics 2010, 125(2):e199-e207.
108. Boom J.A., Tate J.E., Sahni L.C., et al. Sustained protection from pentavalent rotavirus vaccination during the second year of life at a large, urban United States pediatric hospital. Pediatr Infect Dis J 2010, 29(12):1133-1135.
109. Desai S.N., Esposito D.B., Shapiro E.D., et al. Effectiveness of rotavirus vaccine in preventing hospitalization due to rotavirus gastroenteritis in young children in Connecticut, USA. Vaccine 2010, 28(47):7501-7506.
110. Eberly M.D., Gorman G.H., Eide M.B., et al. The effect of rotavirus immunization on rotavirus gastroenteritis hospitalization rates in military dependents. Vaccine 2011, 29(4):650-659.
111. Guh A.Y., Hadler J.L. Use of the state immunization information system to assess rotavirus vaccine effectiveness in Connecticut, 2006-2008. Vaccine 2011, 29(37):6155-6158.
112. Staat M.A., Payne D.C., Donauer S., et al. Effectiveness of pentavalent rotavirus vaccine against severe disease. Pediatrics 2011, 128(2):e267-e275.
113. Wang F.T., Mast T.C., Glass R.J., et al. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. Pediatrics 2010, 125(2):e208-e213.
114. Vesikari T., Karvonen A., Ferrante S.A., et al. Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatr Infect Dis J 2010, 29(10):957-963.
115. Begue R.E., Perrin K. Reduction in gastroenteritis with the use of pentavalent rotavirus vaccine in a primary practice. Pediatrics 2010, 126(1):e40-e45.
116. Chang H.G., Smith P.F., Tserenpuntsag B., et al. Reduction in hospitalizations for diarrhea and rotavirus infections in New York state following introduction of rotavirus vaccine. Vaccine 2010, 28(3):754-758.
117. Clark H.F., Lawley D., Matthijnssens J., et al. Sustained decline in cases of rotavirus gastroenteritis presenting to the Children's Hospital of Philadelphia in the new rotavirus vaccine era. Pediatr Infect Dis J 2010, 29(8):699-702.
118. Cortes J.E., Curns A.T., Tate J.E., et al. Rotavirus Vaccine and Health Care Utilization for Diarrhea in U.S. Children. N Engl J Med 2011, 365(12):1108-1117.
119. Curns A.T., Steiner C.A., Barrett M., et al. Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states. J Infect Dis 2010, 201(11):1617-1624.
120. Custodio H., Masnita-Iusan C., Wludyka P., et al. Change in rotavirus epidemiology in northeast Florida after the introduction of rotavirus vaccine. Pediatr Infect Dis J 2010, 29(8):766-767.
121. Payne D.C., Staat M.A., Edwards K.M., et al. Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US Counties, 2006-2009. Clin Infect Dis 2011, 53(3):245-253.
122. Staat M.A., Rice M.A., Donauer S., et al. Estimating the rotavirus hospitalization disease burden and trends, using capture-recapture methods. Pediatr Infect Dis J 2010, 29(12):1083-1086.
123. Tate J.E., Panozzo C.A., Payne D.C., et al. Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine. Pediatrics 2009, 124(2):465-471.
124. Tate J.E., Mutuc J.D., Panozzo C.A., et al. Sustained decline in rotavirus detections in the United States following the introduction of rotavirus vaccine in 2006. Pediatr Infect Dis J 2011, 30(Suppl 1):S30-S34.
125. Tate J.E., Cortese M.M., Payne D.C., et al. Uptake, impact, and effectiveness of rotavirus vaccination in the United States: review of the first 3 years of postlicensure data. Pediatr Infect Dis J 2011, 30(Suppl 1):S56-S60.
126. Vesikari T., Itzler R., Karvonen A., et al. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine 2009, 28(2):345-351.
127. Curns A.T., Panozzo C.A., Tate J.E., et al. Remarkable postvaccination spatiotemporal changes in United States rotavirus activity. Pediatr Infect Dis J 2011, 30(Suppl 1):S54-S55.
128. Correia J.B., Patel M.M., Nakagomi O., et al. Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil. J Infect Dis 2010, 201(3):363-369.
129. Justino M.C., Linhares A.C., Lanzieri T.M., et al. Effectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belem, Brazil. Pediatr Infect Dis J 2011, 30(5):396-401.
130. Snelling T.L., Andrews R.M., Kirkwood C.D., et al. Case-control evaluation of the effectiveness of the G1P[8] human rotavirus vaccine during an outbreak of rotavirus G2P[4] infection in central Australia. Clin Infect Dis 2011, 52(2):191-199.
131. Field E.J., Vally H., Grimwood K., et al. Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia. Pediatrics 2010, 126(3):e506-e512.
132. Yen C., Figueroa J.R., Uribe E.S., et al. Monovalent Rotavirus Vaccine Provides Protection Against an Emerging Fully Heterotypic G9P[4] Rotavirus Strain in Mexico. J Infect Dis 2011, 204(5):783-786.
133. Carvalho-Costa F.A., Volotao Ede M., de Assis R.M., et al. Laboratory-based rotavirus surveillance during the introduction of a vaccination program, Brazil, 2005-2009. Pediatr Infect Dis J 2011, 30(Suppl 1):S35-S41.
134. Hull J.J., Teel E.N., Kerin T.K., et al. United States rotavirus strain surveillance from 2005 to 2008: genotype prevalence before and after vaccine introduction. Pediatr Infect Dis J 2011, 30(Suppl 1):S42-S47.
135. Kirkwood C.D., Boniface K., Barnes G.L., et al. Distribution of rotavirus genotypes after introduction of rotavirus vaccines, Rotarix(R) and RotaTeq(R), into the National Immunization Program of Australia. Pediatr Infect Dis J 2011, 30(Suppl 1):S48-S53.